scholarly journals Correction to “Performance of a universal prenatal screening program incorporating cell-free fetal DNA analysis in Ontario, Canada”

2021 ◽  
Vol 193 (50) ◽  
pp. E1924-E1924
2021 ◽  
Vol 193 (30) ◽  
pp. E1156-E1163
Author(s):  
Shelley D. Dougan ◽  
Nan Okun ◽  
Kara Bellai-Dussault ◽  
Lynn Meng ◽  
Heather E. Howley ◽  
...  

2021 ◽  
Vol 60 (4) ◽  
pp. 745-751
Author(s):  
M. Rosario Torres Aguilar ◽  
Pilar Carrasco Salas ◽  
Cristina Santos Rosa ◽  
Guadalupe Bueno Rodríguez ◽  
Eduardo Martínez-Bonet ◽  
...  

Genes ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 15
Author(s):  
Luigi Carbone ◽  
Federica Cariati ◽  
Laura Sarno ◽  
Alessandro Conforti ◽  
Francesca Bagnulo ◽  
...  

Fetal aneuploidies are among the most common causes of miscarriages, perinatal mortality and neurodevelopmental impairment. During the last 70 years, many efforts have been made in order to improve prenatal diagnosis and prenatal screening of these conditions. Recently, the use of cell-free fetal DNA (cff-DNA) testing has been increasingly used in different countries, representing an opportunity for non-invasive prenatal screening of pregnant women. The aim of this narrative review is to describe the state of the art and the main strengths and limitations of this test for prenatal screening of fetal aneuploidies.


2021 ◽  
Vol 70 (1) ◽  
pp. 19-50
Author(s):  
Elena A. Kalashnikova ◽  
Andrey S. Glotov ◽  
Elena N. Andreyeva ◽  
Ilya Yu. Barkov ◽  
Galina Yu. Bobrovnik ◽  
...  

This review article offers an analysis of application of cell-free fetal DNA non-invasive prenatal screening test for chromosome abnormalities in the mothers blood in different countries. The diagnostic capacities of the method, its limitations, execution models and ethical aspects pertinent to its application are discussed. The data for the discordant results is shown and analyzed. The advantages of the genome-wide variant of cell-free fetal DNA analysis and the problems concerning its application in the mass screening are described. The main suggestion is to implement the contingent cell-free fetal DNA testing model for the common trisomies (for the chromosomes 21, 18 and 13) into the prenatal diagnostic screening programs in the Russian Federation. This novel model is based on the results of the mass combined first trimester prenatal screening in four federal subjects of the country completed by 2019 and is offered as an additional screening in the mid-level risk group (with cut-off from 1 : 100 to 1 : 500 or from 1 : 100 to 1 : 1000) defined according to the first trimester prenatal screening results. The basic requirements for the implementation of the contingent model in the Russian Federation are stated.


2018 ◽  
Vol 53 (1) ◽  
pp. 87-94 ◽  
Author(s):  
A. J. Vivanti ◽  
J.‐M. Costa ◽  
A. Rosefort ◽  
P. Kleinfinger ◽  
L. Lohmann ◽  
...  

2019 ◽  
Vol 74 (2) ◽  
pp. 61-63
Author(s):  
G. Le Conte ◽  
A. Letourneau ◽  
J. Jani ◽  
P. Kleinfinger ◽  
L. Lohmann ◽  
...  

2014 ◽  
Vol 123 ◽  
pp. 41S
Author(s):  
Alexis Braverman ◽  
Jeffrey S. Dungan ◽  
Norman A. Ginsberg ◽  
Lee P. Shulman

Sign in / Sign up

Export Citation Format

Share Document